Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

Financial Reconciliations

Quarterly Results | Annual Reports | Financial Reconciliations
DateTitle
02/13/19
Download Documentation4Q18 Financial Reconciliations
11/07/18
Download Documentation3Q18 Financial Reconciliations
08/14/18
Download Documentation2018 Meeting with Management Regulation G Financial Reconciliations
08/08/18
Download Documentation2Q18 Financial Reconciliations
05/10/18
Download Documentation1Q18 Financial Reconciliations
02/13/18
Download Documentation4Q17 Financial Reconciliations
11/09/17
Download Documentation3Q17 Financial Reconciliations
08/09/17
Download Documentation2Q17 Financial Reconciliations
05/10/17
Download Documentation1Q17 Financial Reconciliations
02/14/17
Download Documentation4Q16 Financial Reconciliations
11/02/16
Download Documentation3Q16 Financial Reconciliations
08/11/16
Download Documentation2016 Meeting with Management Financial Reconciliations
08/03/16
Download Documentation2Q16 Financial Reconciliations
05/04/16
Download Documentation1Q16 Financial Reconciliations
02/10/16
Download Documentation4Q15 Financial Reconciliations
11/04/15
Download Documentation3Q15 Financial Reconciliations
08/11/15
Download Documentation2015 Meeting with Management Financial Reconciliations
07/30/15
Download Documentation2Q15 Financial Reconciliations
04/30/15
Download Documentation1Q15 Financial Reconciliations
02/11/15
Download Documentation4Q14 Financial Reconciliations
10/30/14
Download Documentation3Q14 Financial Reconciliations
08/07/14
Download Documentation2Q14 Financial Reconciliations
08/07/14
Download Documentation2Q14 Supplemental Schedules
04/30/14
Download Documentation1Q14 Financial Reconciliations
02/12/14
Download Documentation4Q13 Financial Reconciliations
10/30/13
Download Documentation3Q13 Financial Reconciliations
08/01/13
Download Documentation2Q13 Financial Reconciliations
05/02/13
Download Documentation1Q13 Financial Reconciliations
02/14/13
Download Documentation4Q12 Financial Reconciliations
12/13/12
Download Documentation2013 Guidance Financial Reconciliations
10/31/12
Download Documentation3Q12 Financial Reconciliations
08/08/12
Download Documentation2Q12 Financial Reconciliations
05/03/12
Download Documentation1Q12 Financial Reconciliations
02/14/12
Download Documentation4Q11 Financial Reconciliations
12/14/11
Download Documentation2012 Guidance Financial Reconciliations
11/01/11
Download Documentation3Q11 Financial Reconciliations
08/03/11
Download Documentation2Q11 Financial Reconciliations
05/04/11
Download Documentation1Q11 Financial Reconciliations
02/09/11
Download Documentation4Q10 Financial Reconciliations
02/09/11
Download Documentation2010 Quarterly Financial Schedules to Reflect Phase I Business as Discontinued Operation
Get help downloading or viewing the above file types

Stock Quote

CRL (common)
Price
$145.12
Change (%)
- 0.69 (0.47%)
Volume
207,845
Exchange
NYSE
Data as of 03/20/19 4:02 p.m. ET
Data provided by Nasdaq.
Minimum 15 minutes delayed.

Refresh Quote

Investor Hotline

877-567-6CRL (6275)